The National Institutes of Health (NIH) announced a third round of awards to advanced new COVID-19 testing technologies through the Rapid Acceleration of Diagnostics (RADx) Initiative. The $98.35 million will advance six new technologies for point-of-care and other novel test approaches, including new modes of sample collection and the integration with smart devices.
The following were recipients of the third round of awards:
- Ellume USA LLC – Two unique test cartridges contain a single-use, digital fluorescent immunoassay antigen test that returns accurate results in 15 minutes or less
- Luminostics, Inc – A rapid, smartphone-readout, antigen immunoassay that uses glow-in-the-dark nanomaterials to detect COVID-19 from shallow nasal swabs in 30 minutes or less.
- Quanterix – A laboratory antigen test that enables detection from a variety of sample types, including nasopharyngeal, saliva or self-acquired blood from a finger prick. Results can be returned in 24 to 28 hours.
- Flambeau Diagnostics – A lab module device that can be deployed in mobile settings such as work, schools, and underserved populations, to screen asymptomatic individuals.
- Ubiquitome – A battery-operated device that detects viral RNA with high accuracy in 40 minutes and returns results via an iPhone app. The device is targeted for use in rural and metropolitan hospitals and mobile labs.
- Visby – A palm-sized device detects viral RNA with results at the point-of-care within 30 minutes. The product is designed for individuals with minimal skills and can be deployed in many settings.